凌逸虹
专长
姓名：凌逸虹
职称：医学博士，副主任医师，硕士生导师
专长：肿瘤病理诊断
个人简介：本科、硕士及博士均毕业于中山大学。从事肿瘤病理诊断，尤其擅长消化系统肿瘤病理诊断。研究方向为消化系统肿瘤恶性演化机制与个体化治疗。CSCO食管癌病理专业委员会委员、广东省抗癌协会肿瘤靶向治疗专业委员会委员、广东省精准医学应用学会胃肠肿瘤分会常务委员、广东省抗癌协会肿瘤病理青年委员会委员、广东省癌症筛查与早诊早治专业委员会委员、广东省抗癌协会肝癌专业委员会委员及广东省抗癌协会遗传性肿瘤专业委员会委员。长期参加消化系统肿瘤MDT 疑难病理会诊。任消化系统肿瘤（胃肠）病理亚专科秘书。以团队主要成员身份参与并获得中国医师协会MDT专业委员会主办全国胃癌MDT总决赛冠军（两次）。主持国家自然科学基金青年项目一项，指导国家大学生创新项目两项，参与国家四大慢性病重大项目及多项国家自然科学基金青年/面上项目，至今以共同第一/第一作者/通讯作者身份发表20篇SCI收录论著。获中山大学肿瘤防治中心优秀带教老师。“梁伯强-秦光煜病理奖”青年病理工作者获得者。作为第一作者的研究成果被世界卫生组织（WHO）肿瘤学分类（肿瘤分类蓝皮书）引用。
Email：lingyh@sysucc.org.cn
一、教育经历
2004.9-2009.6 中山大学，中山医学院，学士
2009.9-2012.6 中山大学，附属第一医院，硕士
2015.9-2018.6 中山大学，肿瘤防治中心，博士
二、工作经历
2012.9-2016.12 中山大学，肿瘤防治中心，住院医师
2017.1-2021.12 中山大学，肿瘤防治中心，主治医师
2022.1至今 中山大学，肿瘤防治中心，副主任医师
三、部分发表论文
1. Yi-Hong Ling #, Meng-Ni Liu #, Yi-Xin Yin #, Zhong-Guo Zhou#, Jie-Wei Chen, Wei Wei, Jing-Ping Yun, Dan Xie*, Rong-Ping Guo*, Mu-Yan Cai*. Integrated genetic and epigenetic analysis reveals DNA repair alterations in multifocal hepatocellular carcinoma. Signal Transduct Target Ther. 2023, 23;8(1):244.
2. Yihong Ling#, Jian Zhong#, Zelin Weng#, Guangrong Lin#, Caixia Liu, Chuqing Pan, Hong Yang, Xiaolong Wei, Xiuying Xie, Xiaoli Wei, Huizhong Zhang, Geng Wang*, Jianhua Fu*, Jing We*n. The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma. Clin Transl Med. 2022 Oct;12(10):e1074.doi: 10.1002/ctm2.1074.
3. Ruixi, Wang#; Yihong, Ling#; Baoqing, Chen#; Yujia, Zhu; Yonghong, Hu; Mengzhong, Liu; Yadi, Yang; Li, Zhang; Yingxin, Lv; Shiliang, Liu; Qiaoqiao, Li*; Mian, Xi*. Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial. EClinicalMedicine. 10.1016/j.eclinm.2024.102806.
4. Wei Xiao-li#, Liu Qian-wen#, Liu Fu-rong#, Yuan Sha-sha#, Li Xiao-fen, Li Jia-ning , Yang An-Li*, Ling Yi-hong*. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer. Oncoimmunology. 2021, 17;10(1):1938381.
5. Lu Liang-he#, Wei Wei#, Huang Chao-yun#, Li Shao-hua , Zhong Chong, Wang Jia-hong, Yu Wu-sheng, Zhang Yong-fa, Chen Min-shan, Ling Yi-hong*, Rongping Guo*. A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion. Hepatol Int. 2021, 15(3):651-662.
6. Yin YX*, Ling YH*, Wei XL*, He CY, Wang BZ, Hu CF, Lin WP, Nie RC, Chen JW, Lin JL, Zhou J, Xie JJ, Yun JP, Xue LY*, Cai MY*. Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients. Front Immunol. 2022;13(0):973085.
7. Ling Yi-hong#, Chen Jie-wei#, Wen Shi-hong#, Huang Chao-yun, Li Peng, Lu Liang-he, Mei Jie, Li Shao-hua,Wei Wei, Cai Mu-yan*, Guo Rong-ping*. Tumor necrosis as a poor prognostic predictor on postoperative survival of patients with solitary small hepatocellular carcinoma. BMC Cancer. 2020, 29;20(1):607.
8. Ling Yihong #, Zhu ChongMei #, Wen Shihong, Luo Rongzhen, Li Peng, Cao Yun, Rao Huilan, Lin Suxia, Cai Muyan*, Pseudoepitheliomatous hyperplasia mimicking invasive squamous cell carcinoma in extranodal NK/T cell lymphoma: a report of 34 cases, Histopathology, 2015, 67(3):404-409.
更新时间：2025.02.26
